

1 **Supplemental Table 1: Cohort Summary Measures Before and After Matching.** Values  
2 reported are median and inner quartile range for continuous variables or count and percent for  
3 binary variables. SMD is the standardized mean difference or Cohen's *d*, a measure of effect  
4 size. Balance was obtained (absolute value of SMD  $\leq 0.1$ ) on nearly all measures included in  
5 the propensity score model or the disease duration.

6

Variable	Before Matching			After Matching		
	TZ/DZ/AZ (n = 875)	Tamsulosin (n = 4,756)	SMD	TZ/DZ/AZ	Tamsulosin	SMD
<b>Demographics and Timing</b>						
Age (years)	72 (63, 80)	74 (64, 81)	-0.08	72 (63, 80)	72 (62, 81)	0.01
RX Start Year	2003 (2001, 2006)	2004 (2001, 2008)	-0.02	2004 (2001, 2006)	2004 (2002, 2008)	0.01
Lookback (years)	3.8 (2.2, 6.4)	4.8 (2.7, 7.8)	-0.26	4.3 (2.5, 6.8)	3.9 (2.3, 6.0)	0.19
Follow-Up (years)	1.8 (0.9, 4.1)	2.0 (0.9, 2.8)	-0.01	2.0 (0.9, 4.2)	1.9 (0.9, 4.1)	0.00
PD Disease Duration (years)	2.35 (1.53, 3.99)	2.74 (1.72, 4.60)	-0.18	2.57 (1.68, 4.25)	2.47 (1.66, 3.97)	0.10
<b>Baseline Healthcare Utilization</b>						
Inpatient Visits Per Year	0.14 (0.00, 1.34)	0.35 (0.00, 1.67)	-0.10	0.25 (0.00, 1.41)	0.13 (0.00, 1.48)	-0.13
Outpatient Visits Per Year	17 (10, 27)	17 (10, 27)	-0.01	17 (11, 28)	16 (9, 27)	0.01
Mean Number of Unique DX	0.35 (0.20, 0.62)	0.31 (0.17, 0.57)	0.05	0.31 (0.19, 0.56)	0.36 (0.21, 0.60)	-0.08
Outpatient DX Code Incidence	22 (14, 38)	25 (15, 42)	-0.10	23 (14, 39)	22 (12, 38)	0.00
<b>Elixhauser Comorbidities</b>						
Alcohol Abuse	12 (1.4%)	117 (2.5%)	-0.07	12 (1.6%)	13 (1.7%)	-0.01
Anemia	219 (25.0%)	1,204 (25.3%)	-0.01	201 (26.7%)	177 (23.5%)	0.07
Blood Loss	18 (2.1%)	130 (2.7%)	-0.04	16 (2.1%)	15 (2.0%)	0.01
Heart Failure	156 (17.8%)	923 (19.4%)	-0.04	138 (18.3%)	144 (19.1%)	-0.02
Coagulopathy	50 (5.7%)	309 (6.5%)	-0.03	46 (6.1%)	32 (4.2%)	0.09
Depression	143 (15.3%)	841 (17.7%)	-0.06	127 (16.8%)	106 (14.1%)	0.08
Diabetes W/O Complications	312 (35.7%)	1,545 (32.5%)	0.07	287 (38.1%)	247 (32.8%)	0.11
Diabetes W/ Complications	146 (16.7%)	752 (15.8%)	0.02	134 (17.8%)	103 (13.7%)	0.11
Drug Abuse	8 (0.9%)	81 (1.7%)	-0.06	6 (0.8%)	19 (2.5%)	-0.14
Fluid/Electrolyte Disorders	160 (18.3%)	993 (20.9%)	-0.06	147 (19.5%)	138 (18.3%)	0.03
HIV	3 (0.3%)	7 (0.1%)	0.05	3 (0.4%)	1 (0.1%)	0.05
HTN W/O Complications	623	3,310	0.04	555	528	0.08

HTN W/ Complications	(71.2%) 169	(69.6%) 875	0.02	(73.6%) 159	(70.0%) 134	0.08
Hypothyroidism	(19.3%) 97	(18.4%) 641	-0.07	(21.1%) 95	(17.8%) 97	-0.01
Liver Disease	(11.1%) 38	(13.5%) 210	0.00	(12.6%) 36	(12.9%) 29	0.05
Lymphoma	(4.3%) 20	(4.4%) 94	0.02	(4.8%) 20	(3.8%) 13	0.06
Metastatic Cancer	(2.3%) 14	(2.0%) 120	-0.06	(2.7%) 14	(1.7%) 18	-0.04
Other Neurological Disorders	(1.6%) 626	(2.5%) 3,788	-0.20	(1.9%) 548	(2.4%) 511	0.11
Obesity	(71.5%) 45	(79.6%) 381	-0.11	(72.7%) 44	(67.8%) 33	0.07
Paralysis	(5.1%) 39	(8.0%) 267	-0.05	(5.8%) 36	(4.4%) 29	0.05
Pulmonary/Circ Disorders	(4.5%) 38	(5.6%) 244	-0.04	(4.8%) 35	(3.8%) 42	-0.04
Psychoses	(4.3%) 94	(5.1%) 568	-0.04	(4.6%) 89	(5.6%) 81	0.03
Peptic Ulcer Disease	(10.7%) 2	(11.9%) 22	-0.04	(11.8%) 2	(10.7%) 3	-0.02
COPD	(0.2%) 256	(0.5%) 1,536	-0.07	(0.3%) 226	(0.4%) 220	0.02
Peripheral Vascular Disease	(29.3%) 205	(32.3%) 1,329	-0.10	(30.0%) 193	(29.2%) 179	0.04
Renal Failure	(23.4%) 124	(27.9%) 507	0.11	(25.6%) 117	(23.7%) 108	0.03
Rheumatoid Arthritis	(14.2%) 44	(10.7%) 410	-0.13	(15.5%) 40	(14.3%) 40	0.00
Solid Tumor	(5.0%) 152	(8.6%) 991	-0.09	(5.3%) 130	(5.3%) 133	-0.01
Valvular Disease	(17.4%) 176	(20.8%) 1,193	-0.12	(17.2%) 170	(17.6%) 158	0.04
Weight Loss	(20.1%) 67	(25.1%) 501	-0.10	(22.5%) 57	(21.0%) 64	-0.03
	(7.7%)	(10.5%)		(7.6%)	(8.5%)	
<b>Prescribing Specific Considerations</b>						
<b>Indications</b>						
PSA Measurement Taken	411	1,998	0.10	348	343	0.01
	(47.0%)	(42.0%)		(46.2%)	(45.5%)	
Abnormal PSA	109	721	-0.08	95	103	-0.03
	(12.5%)	(15.2%)		(12.6%)	(13.7%)	
Slow Urinary Stream	25	139	0.00	23	19	0.03
	(2.9%)	(2.9%)		(3.1%)	(2.5%)	
Uroflow Study	89	424	0.04	84	62	0.10
	(10.2%)	(8.9%)		(11.1%)	(8.2%)	
Cystometrogram	29	118	0.05	25	21	0.03
	(3.3%)	(2.5%)		(3.3%)	(2.8%)	
Diagnosis of BPH	365	2,043	-0.03	323	305	0.05
	(41.7%)	(43.0%)		(42.8%)	(40.5%)	
<b>Adverse Event Risks</b>						
Orthostatic Hypotension	28	276	-0.12	27	35	-0.05
	(3.2%)	(5.8%)		(3.6%)	(4.6%)	
Other Hypotension	45	375	-0.10	41	35	-0.04
	(5.1%)	(7.9%)		(5.4%)	(4.6%)	